CN105120663B - 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 - Google Patents

用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 Download PDF

Info

Publication number
CN105120663B
CN105120663B CN201480019712.6A CN201480019712A CN105120663B CN 105120663 B CN105120663 B CN 105120663B CN 201480019712 A CN201480019712 A CN 201480019712A CN 105120663 B CN105120663 B CN 105120663B
Authority
CN
China
Prior art keywords
cancer
purposes
medicine
acquired resistance
targeted drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480019712.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105120663A (zh
Inventor
拉希达·A·卡马利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KARMALI RASHIDA Co
Original Assignee
KARMALI RASHIDA Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KARMALI RASHIDA Co filed Critical KARMALI RASHIDA Co
Publication of CN105120663A publication Critical patent/CN105120663A/zh
Application granted granted Critical
Publication of CN105120663B publication Critical patent/CN105120663B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480019712.6A 2013-04-01 2014-03-28 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 Active CN105120663B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/986,103 US9089570B2 (en) 2010-09-03 2013-04-01 Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US13/986,103 2013-04-01
PCT/US2014/032253 WO2014165412A2 (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
CN105120663A CN105120663A (zh) 2015-12-02
CN105120663B true CN105120663B (zh) 2017-08-04

Family

ID=51621074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480019712.6A Active CN105120663B (zh) 2013-04-01 2014-03-28 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物

Country Status (10)

Country Link
US (1) US9089570B2 (enExample)
EP (1) EP2981169B1 (enExample)
JP (1) JP6410795B2 (enExample)
KR (2) KR20210019116A (enExample)
CN (1) CN105120663B (enExample)
AU (1) AU2014248377B2 (enExample)
CA (1) CA2902144C (enExample)
IL (1) IL241827B (enExample)
WO (1) WO2014165412A2 (enExample)
ZA (1) ZA201506037B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015095A1 (en) * 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN107890467A (zh) * 2017-11-24 2018-04-10 中国医学科学院基础医学研究所 干扰能量代谢的药物在胰腺癌复发中的应用
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
WO2024208247A1 (zh) * 2023-04-04 2024-10-10 广东银珠医药科技有限公司 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途
WO2024235217A1 (zh) * 2023-05-15 2024-11-21 广东银珠医药科技有限公司 一种抗肺癌联合用药物及其应用
CN119971050A (zh) * 2023-11-10 2025-05-13 广东银珠医药科技有限公司 羧胺三唑与化疗药的组合物及联用治疗实体瘤的用途
WO2025214445A1 (zh) * 2024-04-12 2025-10-16 广东银珠医药科技有限公司 一种三氮唑类化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578099A (zh) * 2006-12-06 2009-11-11 巧妙疗法股份有限公司 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途
CN101669941A (zh) * 2008-09-09 2010-03-17 中国医学科学院基础医学研究所 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
CN102595904A (zh) * 2009-09-04 2012-07-18 巧妙疗法股份有限公司 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
US20120202760A1 (en) * 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122782A (en) * 1995-07-21 2003-03-12 Gruppe Constantia Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
EP2193135A1 (en) * 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578099A (zh) * 2006-12-06 2009-11-11 巧妙疗法股份有限公司 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途
CN101669941A (zh) * 2008-09-09 2010-03-17 中国医学科学院基础医学研究所 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
CN102595904A (zh) * 2009-09-04 2012-07-18 巧妙疗法股份有限公司 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
US20120202760A1 (en) * 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Also Published As

Publication number Publication date
US9089570B2 (en) 2015-07-28
CA2902144A1 (en) 2014-10-09
EP2981169A2 (en) 2016-02-10
CA2902144C (en) 2021-02-09
AU2014248377B2 (en) 2018-02-01
ZA201506037B (en) 2021-09-29
HK1214921A1 (zh) 2016-08-12
JP2016515619A (ja) 2016-05-30
IL241827B (en) 2019-02-28
JP6410795B2 (ja) 2018-10-24
EP2981169A4 (en) 2016-09-14
KR20210019116A (ko) 2021-02-19
US20140294806A1 (en) 2014-10-02
CN105120663A (zh) 2015-12-02
KR20160026824A (ko) 2016-03-09
WO2014165412A3 (en) 2015-01-29
AU2014248377A1 (en) 2015-09-03
EP2981169B1 (en) 2021-05-05
WO2014165412A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CN105120663B (zh) 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物
CN103533961B (zh) 以表皮生长因子受体为靶向的治疗癌症的组合方法
CN102740851B (zh) Pi3k抑制剂和mek抑制剂的组合
AU2012229062A1 (en) Overcoming resistance to ErbB pathway inhibitors
Mosquera et al. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials
CN111643503A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
US20210015787A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Caban et al. A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo
US20250262214A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
Duenas-Gonzalez et al. Pharmacotherapy options for locally advanced and advanced cervical cancer
Yazdi et al. Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
Lin et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
JP2025505705A (ja) がんの処置における使用のためのＩＧＦ１Ｒ阻害剤及びＡｋｔ阻害剤
Huang et al. Molecular targeting of growth factor receptor signaling in radiation oncology
Wang et al. Polypharmacology in Clinical Applications—Anticancer Polypharmacology
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate
HK1214921B (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Rawat Design and Synthesis of Benzimidazole Derivatives as Anti-Cancer Agents
Jemel et al. The offer of chemistry to targeted therapy in cancer
Park et al. Updates on AKT Inhibition in Estrogen Receptor Positive Breast Cancer
Hookes et al. 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: November 12-16, 2011, San Francisco, CA, USA
Sleijfer P Hamberg J Verweij

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant